Decentralized clinical trials gained a foothold in the pharmaceutical industry amidst the COVID-19 pandemic and will continue to be used once the pandemic ends, according to panelists at BIO 2020.
Biopharmaceutical companies need to look beyond the usual targets when addressing neurodegenerative disorders and also must work to correlate genetic changes to cognitive changes in patients, according to panelists at BIO’s on-demand session, “Battle of the Brains: Rethinking Neurodegenerative Disease Treatment.”
BIO 2020: Day 1 Kicked Off With New CEO, Focus on COVID-19 Published: June 9, 2020 By Alex Keown BioSpace The annual Biotechnology Innovation Organization (BIO) meeting kicked off Monday with the proverbial passing of the baton from longtime head Jim Greenwood to Michelle McMurry-Heath, who was tapped to take over the organization last month. […]
One day, cell and gene therapies will be as common as small molecules and antibody-based therapies are today, according to panelists at BIO 2020.
The Biotechnology Innovation Organization (BIO)’s annual meeting brings together some of the brightest minds across the industry to showcase advancements in developing therapeutics that will benefit people battling a myriad of diseases. The 2020 event, which kicks off June 8, will have a different look as an entirely digital conference.
BIO and TEConomy Partners released their 2018 “Investment, Innovation and Job Creation in a Growing U.S. Bioscience Industry” report.
At the 2018 BIO International Convention in Boston, FDA Commissioner Dr. Scott Gottlieb said he expects the U.S. regulatory agency to approve 40 gene therapies by 2022.